Trastuzumab, an anti-HER2 antibody, is too large to penetrate the BBB but is very effective extracranially and prolongs the survival of BC patients; however, it increases the risk of metastasis to the CNS as the first relapse location (104). Here, ERBB2 is linked to breast cancer.